Bausch + Lomb, a leading global health and wellness company, announced its plans to further expand its surgical business product portfolio in India. The development is in line with the company’s strategy to extend and strengthen its presence in the growing ophthalmology surgical devices and instruments market in the country.
“We are pleased to further reinforce our commitment of adding and delivering world-class, innovative surgical devices and instruments to serve the needs of our community and patients. The addition of Synergetics’ product portfolio will further consolidate our presence in India’s expanding sector of vitreoretinal surgery,” said Sanjay Bhutani, managing director, India & SAARC, Bausch + Lomb India.
Bausch + Lomb plans to launch its state of art product VersaVIT 2.0 Vitrectomy System, along with all the instruments and accessories ranging from illumination probes, packs, laser probes, filters, cannulas and other instruments.
Bausch + Lomb offers world-class and technological most advanced surgical equipment for cataract and refractive surgeries through platforms like Stellaris Vision Enhancement System, Teneo 317 excimer laser and Victus femtosecond laser with latest technologies for procedures like SUPRACOR and Zyoptix.
“Synergetics’ business completely aligns with our business, which will enable us to offer an even wider range of products across cataract, vitreoretinal and refractive surgeries,” said Premal Pandya, commercial director, ophthalmology and aesthetics, Bausch + Lomb India.
According to Persistence Market Research, the global ophthalmic devices market will grow from an estimated USD 29.7 billion in 2014 to USD 42.7 billion in 2020 at CAGR of 6.5 per cent during the forecast period.
Glaucoma, cataract and diabetes retinopathy are the major causes of blindness in Asia, with India alone accounting for over 12 million glaucoma patients. India has more than 10 million blind citizens and an average of 2 million new cases added each year. The reason for blindness in 60 per cent people is cataract and 13 per cent lose sight due to glaucoma.